Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway

[1]  B. Challacombe,et al.  Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross‐sectional, UK epidemiological study , 2016, BJU international.

[2]  Young Ock Kim,et al.  Association between polymorphisms of estrogen receptor 2 and benign prostatic hyperplasia. , 2015, Experimental and therapeutic medicine.

[3]  Zhiping Wang,et al.  Metabolic Syndrome, Inflammation and Lower Urinary Tract Symptoms – Possible Translational Links , 2015, Prostate Cancer and Prostatic Disease.

[4]  T. Edwards,et al.  Genetic Determinants of Metabolism and Benign Prostate Enlargement: Associations with Prostate Volume , 2015, PloS one.

[5]  P. Rajan,et al.  Systematic Review and Meta-analysis of Candidate Gene Association Studies of Lower Urinary Tract Symptoms in Men , 2014, European urology.

[6]  Satyender Singh,et al.  Association of CYP1A1, CYP1B1 and CYP17 gene polymorphisms and organochlorine pesticides with benign prostatic hyperplasia. , 2014, Chemosphere.

[7]  R. Wolff,et al.  CYP19A1 single nucleotide polymorphism associations with CYP19A1, NFκB1, and IL6 gene expression in human normal colon and normal liver samples , 2014, Pharmacogenomics and personalized medicine.

[8]  C. Guillemette,et al.  Steroidogenic Germline Polymorphism Predictors of Prostate Cancer Progression in the Estradiol Pathway , 2014, Clinical Cancer Research.

[9]  Alexander Bachmann,et al.  EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. , 2013, European urology.

[10]  W. Catalona,et al.  Genetic sequence variants are associated with severity of lower urinary tract symptoms and prostate cancer susceptibility. , 2013, The Journal of urology.

[11]  C. Guillemette,et al.  The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy. , 2012, European urology.

[12]  J. Macoska.  Chemokines and BPH/LUTS. , 2011, Differentiation; research in biological diversity.

[13]  J. Macoska,et al.  Developmental, cellular and molecular biology of benign prostatic hyperplasia. , 2011, Differentiation; research in biological diversity.

[14]  M. Freeman,et al.  Cholesterol and benign prostate disease. , 2011, Differentiation; research in biological diversity.

[15]  W. Ricke,et al.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future. , 2011, Differentiation; research in biological diversity.

[16]  W. Bushman,et al.  Role of interleukins, IGF and stem cells in BPH. , 2011, Differentiation; research in biological diversity.

[17]  A. Gylfason,et al.  Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels , 2010, Science Translational Medicine.

[18]  F. Habib,et al.  Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. , 2008, The Journal of endocrinology.

[19]  C. Langefeld,et al.  Comprehensive evaluation of the estrogen receptor α gene reveals further evidence for association with type 2 diabetes enriched for nephropathy in an African American population , 2008, Human Genetics.

[20]  F. Hamdy,et al.  Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Fearnhead,et al.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 , 2007, Nature Genetics.

[22]  S. Inoue,et al.  Zone-Dependent Expression of Estrogen Receptors and in Human Benign Prostatic Hyperplasia , 2003 .

[23]  K. Korach,et al.  Prostate phenotypes in estrogen-modulated transgenic mice , 2002, Trends in Endocrinology & Metabolism.

[24]  Hong Wang,et al.  Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. , 2001, Endocrinology.

[25]  L. Andersson,et al.  A role for estrogen receptor β in the regulation of growth of the ventral prostate , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  V. Rossi,et al.  Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. , 2001, The Journal of clinical endocrinology and metabolism.

[27]  F. Bethencourt,et al.  Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. , 2001, The Journal of endocrinology.

[28]  A. Meikle,et al.  Heritability of the symptoms of benign prostatic hyperplasia and the roles of age and zonal prostate volumes in twins. , 1999, Urology.

[29]  J. Gustafsson,et al.  Generation and reproductive phenotypes of mice lacking estrogen receptor beta. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  T. Beaty,et al.  Clinical and biological characteristics of familial benign prostatic hyperplasia. , 1997, The Journal of urology.

[31]  P. Walsh,et al.  The development of human benign prostatic hyperplasia with age. , 1984, The Journal of urology.

[32]  C. Roehrborn.  Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). , 2011, The Medical clinics of North America.

[33]  F. Habib,et al.  Estrogen and androgen signaling in the pathogenesis of BPH , 2011, Nature Reviews Urology.

[34]  H. Koyuncu,et al.  The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. , 2007, European urology.

[35]  H. Lepor.  Pathophysiology of lower urinary tract symptoms in the aging male population. , 2005, Reviews in urology.

[36]  S. Inoue,et al.  Zone-dependent expression of estrogen receptors alpha and beta in human benign prostatic hyperplasia. , 2003, The Journal of clinical endocrinology and metabolism.